Novo amps up 2012 expectations on strong Victoza sales

Novo Nordisk ($NVO) boosted its sales outlook for 2012 after sales of the diabetes drug Victoza more than doubled to 2.1 billion crowns, beating analyst estimates. It's counting on new long-acting insulins that are awaiting approval to help it compete with Amylin Pharmaceuticals' ($AMLN) newly approved weekly injection Bydureon. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…